Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells

Journal of Cellular Biochemistry

Volumn 104, Issue 5, 2008, Pages 1636-1646

  Yoo, Jinsang ^a   Park, Sung Soo ^a   Lee, Yong J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bcl 2; Caspase; Docetaxel; Hormone refractory prostate cancer; TRAIL

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE; DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; CYCLIN B; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTRACELLULAR SPACE; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 8; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 50249095026     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21729     Document Type: Article

References (51)

1. Abuharbeid S, Apel J, Zugmaier G, Knabbe C, Sander M, Gilbert S, Czubayko F, Aigner A. 2005. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 371:141-151.
2. Ashkenazi A, Dixit VM. 1999. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260.
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig 104:155-162.
4. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. 2007. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 6:1387-1399.
5. Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, Masci RK, Lee RM, Didonato JA, Lindner DJ. 2007. Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS ONE 2:el313.
6. Bissett D, Kaye SB. 1993. Taxol and taxotere-current status and future prospects. Eur J Cancer 29A:1228-1231.
7. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A. 2003. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: Resensitisation with chemotherapy. Br J Cancer 7:206-214.
8. Brichese L, Cazettes G, Valette A. 2004. JNK is associated with Bcl-2 and PP1 in mitochondria: Paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2. Cell Cycle 3:1312-1319.
9. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS. 1998. Cancer Res 58:4940-4946.
10. Calabro F, Sternberg CN. 2007. Current indications for chemotherapy in prostate cancer patients. Eur Urol 51:17-26.
11. Chawla-Sarkar M, Bauer JA, Lupica JA, Morrison BH, Tang Z, Oates RK, Almasan A, DiDonato JA, Borden EC, Lindner DJ. 2003. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 278:39461-39469.
12. Chen YC, Lu PH, Pan SL, Teng CM, Kuo SC, Lin TP, Ho YF, Huang YC, Guh JH. 2007. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdkl-involved signaling pathways. Biochem Pharmacol 74:10-19.
13. Chowdhury S, Burbridge S, Harper PG. 2007. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract 61:2064-2070.
14. Clarke NW. 2006. Management of the spectrum of hormone refractory prostate cancer. Eur Urol 50:428-439.
15. Cory S, Huang DC, Adams JM. 2003. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 22:8590-8607.
16. Curtin JF, Cotter TG. 2003. Defects in death-inducing signalling complex formation prevent JNK activation and Fas-mediated apoptosis in DU 145 prostate carcinoma cells. Br J Cancer 89:1950-1957.
17. Das A, Banik NL, Ray SK. 2007. Differentiation decreased telomerase activity in rat glioblastoma C6 cells and increased sensitivity to IFN-gamma and taxol for apoptosis. Neurochem Res 32:2167-2183.
18. Das A, Banik NL, Ray SK. 2008. Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 87:9-22.
19. de Jong S, Timmer T, Heijenbrok FJ, de Vries EG. 2001. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 20:51-56.
20. Estève MA, Carré M, Bourgarel-Rey V, Kruczynski A, Raspaglio G, Ferlini C, Braguer D. 2006. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther 5:2824-2833.
21. Fulda S, Jeremias I, Debatin KM. 2004. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 23:7611-7620.
22. Goktas S, Ziada A, Crawford ED. 1999. Combined androgen blockade for advanced prostatic carcinoma. Prostate Cancer Prostatic Dis 2:172-179.
23. Gomez LA, de Las Pozas A, Reiner T, Burnstein K, Perez-Stable C. 2007. Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Mol Cancer Ther 6:1534-1543.
24. Hadaschik BA, Sowery RD, Gleave ME. 2007. Novel targets and approaches in advanced prostate cancer. Curr Opin Urol 17:182-187.
25. Haldar S, Jena N, Croce CM. 1994. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem Cell Biol 72:455-462.
26. Haldar S, Jena N, Croce CM. 1995. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-4511.
27. Isaacs JT, Furuya Y, Berges R. 1994. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5:391-400.
28. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics 2007. CA Cancer J Clin 57:43-66.
29. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ. 2005. Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J. Biol Chem 280:41047-41056.
30. Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, Kim TH, Billiar TR, Song YK. 2001. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 20:1476-1485.
31. Mhaidat NM, Zhang XD, Jiang CC, Hersey P. 2007. Docetaxel-induced apoptosis of human melanoma is mediated by activation of JNK and inhibited by the MAP kinase ERK1/2 pathway. Clin Cancer Res 13:1308-1314.
32. Nicolini G, Rigolio R, Scuteri A, Miloso M, Saccomanno D, Cavaletti G, Tredici G. 2003. Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int 42:419-429.
33. Nyormoi O, Mills L, Bar-Eli M. 2003. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 10:558-569.
34. Park SY, Billiar TR, Seol DW. 2002. IFN-gamma inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-gamma-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 291:233-236.
35. Petrylak DP. 1999. Chemotherapy for advanced hormone refractory prostate cancer. Urology 54:30-35.
36. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. 2004. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520.
37. Pisters LL. 1999. The challenge of locally advanced prostate cancer. Semin Oncol 26:202-216.
38. Prostate Cancer Trialists' Collaborative Group. 2000. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 29:1491-1498.
39. Richie JP. 1999. Anti-androgens and other hormonal therapies for prostate cancer. Urology 54:15-18.
40. Shiah SG, Chuang SE, Kuo ML. 2001. Involvement of Asp-Glu-Val-Asp- directed, caspase-mediated mitogen-acti-vated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol 59:254-262.
41. Sui M, Xiong X, Kraft AS, Fan W. 2006. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther 5:1015-1021.
42. Suzuki Y, Kondo Y, Himeno S, Nemoto K, Akimoto M, Imura N. 2000. Role of antioxidant systems in human androgen-independent prostate cancer cells. Prostate 43:144-149.
43. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators. 2004. Docetaxel plus prednisone or itoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512.
44. Thalmann GN, Anezinis PA, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581.
45. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. 2000. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 44:91-103.
46. Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA. 2003. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 63:5118-5125.
47. Vassilev LT. 2005. p53 Activation by small molecules: Application in oncology. J Med Chem 48:4491-4499.
48. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. 1994. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 57:406-412.
49. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y. 2007. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 98:1969-1976.
50. Yamamoto K, Ichijo H, Korsmeyer SJ. 1999. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 19:8469-8478.
51. Yoo J, Lee YJ. 2008. Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells. J Cell Biochem 103:98-109.